1. Home
  2. BEAM vs GTY Comparison

BEAM vs GTY Comparison

Compare BEAM & GTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • GTY
  • Stock Information
  • Founded
  • BEAM 2017
  • GTY 1955
  • Country
  • BEAM United States
  • GTY United States
  • Employees
  • BEAM N/A
  • GTY N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • GTY Real Estate
  • Sector
  • BEAM Health Care
  • GTY Finance
  • Exchange
  • BEAM Nasdaq
  • GTY Nasdaq
  • Market Cap
  • BEAM 1.7B
  • GTY 1.6B
  • IPO Year
  • BEAM 2020
  • GTY N/A
  • Fundamental
  • Price
  • BEAM $17.46
  • GTY $28.09
  • Analyst Decision
  • BEAM Strong Buy
  • GTY Buy
  • Analyst Count
  • BEAM 10
  • GTY 6
  • Target Price
  • BEAM $48.56
  • GTY $32.33
  • AVG Volume (30 Days)
  • BEAM 2.4M
  • GTY 390.7K
  • Earning Date
  • BEAM 08-05-2025
  • GTY 07-23-2025
  • Dividend Yield
  • BEAM N/A
  • GTY 6.69%
  • EPS Growth
  • BEAM N/A
  • GTY N/A
  • EPS
  • BEAM N/A
  • GTY 1.15
  • Revenue
  • BEAM $60,272,000.00
  • GTY $210,071,000.00
  • Revenue This Year
  • BEAM N/A
  • GTY $4.91
  • Revenue Next Year
  • BEAM $17.18
  • GTY $7.03
  • P/E Ratio
  • BEAM N/A
  • GTY $24.45
  • Revenue Growth
  • BEAM N/A
  • GTY 6.62
  • 52 Week Low
  • BEAM $13.53
  • GTY $26.42
  • 52 Week High
  • BEAM $35.25
  • GTY $33.85
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 39.16
  • GTY 49.85
  • Support Level
  • BEAM $16.65
  • GTY $27.88
  • Resistance Level
  • BEAM $21.40
  • GTY $28.39
  • Average True Range (ATR)
  • BEAM 1.00
  • GTY 0.44
  • MACD
  • BEAM -0.35
  • GTY 0.03
  • Stochastic Oscillator
  • BEAM 13.89
  • GTY 45.56

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About GTY Getty Realty Corporation

Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.

Share on Social Networks: